Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOBIOTIC: Probiotics for Preventing Antibiotic-Associated Diarrhea
NCT03755765Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial of bifidobacterium animalis subsp. lactis bb-12 in antibiotic-associated diarrhea (AAD) (2 arms), sponsored by Georgetown University. Primary endpoint: Level of Fecal Short-chain Fatty Acid (SCFA) Acetate at day 30. Started Jul 2019; status: completed.
02
Drugs
bifidobacterium animalis subsp. lactis bb-12
03
Conditions
antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on NCT03755765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755765.